Georganna Starnes, MD
Family Medicine · Morristown, TNNPI 1710299854
Payments from drug & device makers
Across 475 payments — averaging $14.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$1K
- Lilly USA, LLC$641
- Amgen$500
- Pfizer$331
- GSK$316
- plus $3K from 28 others
What the payments were for
- Food & beverage$6,768100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 106 | $1,251 |
| Novo Nordisk | 87 | $1,090 |
| Lilly USA, LLC | 39 | $641 |
| Amgen | 34 | $500 |
| Pfizer | 28 | $331 |
| GSK | 20 | $316 |
| Merck | 17 | $300 |
| Bayer | 16 | $266 |
| Novartis | 16 | $238 |
| Boehringer Ingelheim | 14 | $205 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $160 |
| Xeris Pharmaceuticals, Inc. | 8 | $148 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $147 |
| MDD US Operations, LLC | 7 | $142 |
| Johnson & Johnson | 11 | $141 |
| Dexcom, Inc. | 7 | $134 |
| Mylan Specialty L.p. | 7 | $106 |
| Astellas Pharma US Inc | 5 | $82 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $75 |
| AstraZeneca | 5 | $72 |
| Biohaven Pharmaceuticals, Inc. | 3 | $51 |
| Ardelyx, Inc. | 3 | $50 |
| Otsuka America Pharmaceutical, Inc. | 3 | $49 |
| Esperion Therapeutics, Inc. | 3 | $46 |
| Axsome Therapeutics, Inc. | 2 | $45 |
| Vanda Pharmaceuticals Inc. | 2 | $43 |
| Sumitomo Pharma America, Inc. | 2 | $32 |
| Teva Pharmaceuticals USA, Inc. | 2 | $28 |
| Alkermes, Inc. | 1 | $24 |
| Exact Sciences | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
| Eisai Inc. | 1 | $11 |
How this compares
$6,780 in reported general payments places this provider in the 85th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 206 | $263,232 |
| TrulicityDulaglutide | 130 | $160,230 |
| EliquisApixaban | 137 | $131,568 |
| VraylarCariprazine Hcl | 64 | $91,200 |
| OzempicSemaglutide | 66 | $86,174 |
| LinzessLinaclotide | 102 | $86,000 |
| FarxigaDapagliflozin Propanediol | 75 | $74,746 |
| EntrestoSacubitril/Valsartan | 47 | $65,913 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 65 | $58,957 |
| JardianceEmpagliflozin | 53 | $58,248 |
| RexultiBrexpiprazole | 35 | $52,158 |
| Humalog Kwikpen U-200Insulin Lispro | 27 | $38,696 |
| JanuviaSitagliptin Phosphate | 29 | $31,620 |
| XareltoRivaroxaban | 43 | $28,817 |
| Repatha SyringeEvolocumab | 33 | $23,419 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $641 | $423,462336 claims |
| AbbVieVraylar, Linzess, Ubrelvy, Qulipta, Fetzima | $1,251 | $221,994210 claims |
| PfizerEliquis | $331 | $131,568137 claims |
| Novo NordiskOzempic, Rybelsus | $1,090 | $103,72084 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $72 | $91,866103 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $205 | $80,06080 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $316 | $75,96196 claims |
| NovartisEntresto | $238 | $65,91347 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $49 | $52,15835 claims |
| MerckJanuvia, Belsomra | $300 | $51,10473 claims |
| Johnson & JohnsonXarelto | $141 | $28,81743 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $32 | $22,22623 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Morristown
- Derek CoozeMorristown$40K
- Justin GarrisonMorristown$35K
- Rickey ManningKnoxville$8.1M
- Kymberly MoyerGallatin$5.9M
- Natasha BallardChattanooga$5.7M
- Hina BudhwaniNashville$4.7M
- Paul WakefieldKnoxville$4.3M
- Emily HubbsKingsport$2.8M
- Jerry PunchKnoxville$2.1M
- Bridgette FraneyNashville$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.